Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼¼±âÁ¶Àý¹æ»ç¼±Ä¡·á(IMRT)·Î Ä¡·áÇÑ Incidence and Prognostic Factors of Radiation Pneumonitis

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2008³â 26±Ç 1È£ p.35 ~ 44
±è¸í¼¼,
¼Ò¼Ó »ó¼¼Á¤º¸
±è¸í¼¼ ( Kim Myung-Se ) 
¿µ³²´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç

Abstract

¸ñÀû: ¼¼±âÁ¶Àý¹æ»ç¼±Ä¡·á·Î Ä¡·áÇÑ ºñ¼Ò¼¼Æ÷Æó¾Ï ȯÀÚ¿¡¼­ ¹æ»ç¼± Æó·ÅÀÇ ¹ß»ý·ü°ú ¿µÇâÀ» ¹ÌÄ¡´Â ¿äÀÎÀ» ºÐ¼® ÇÏ°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 2004³â 8¿ù 1ÀϺÎÅÍ 2006³â 11¿ù 30ÀϱîÁö ºñ¼Ò¼¼Æ÷Æó¾ÏÀ¸·Î È®ÁøµÇ°í ¼¼±âÁ¶Àý¹æ»ç¼±Ä¡·á·Î Ä¡·áÇÑ È¯ÀÚ 105¸íÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. Æò±Õ¿¬·ÉÀº 62.9¼¼¿´°í ÆíÆò»óÇǾÏÀÌ 81¸í(77%)À̾ú°í, III±â ȯÀÚ°¡ 66¸íÀ¸·Î(62.9%) °¡Àå ¸¹¾ÒÀ¸¸ç ¿ìÃø Æó¿¡ º´¼Ò¸¦ °¡Áø ȯÀÚ´Â 59¸í, ÁÂÃø Æó´Â 46¸íÀ̾ú´Ù. ¼ö¼ú Àü ¹æ»ç¼± Ä¡·á·Î 3,060 cGy¸¦ Á¶»ç¹ÞÀº ȯÀÚ´Â 27¸í, ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á·Î 5,040 cGy¸¦ Á¶»ç¹ÞÀº ȯÀÚ´Â10¸íÀ̾ú°í 7,020 cGyÀÇ ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº ȯÀÚ´Â 68¸íÀ̾ú´Ù. Ä¡·á°èȹÀº CORVUS ½Ã½ºÅÛÀÌ 68¸í, ECLIPSE ½Ã½ºÅÛÀÌ 37¸íÀ̾ú´Ù.

°á°ú: ¹æ»ç¼± Æó·Å ȤÀº ¹æ»ç¼± Ä¡·á¿Í °ü·ÃµÈ º´¸®ÇÐÀû ÀÌ»ó ¼Ò°ßÀ¸·Î º»¿ø ¿µ»óÀÇÇаú¿¡¼­ Áø´ÜµÈ ȯÀÚ´Â 21¸í(20%)À̾úÀ¸³ª, Áõ»óÀÌ ÀÖ¾î Ä¡·á¸¦ ¹ÞÀº »ç¶÷Àº 7¸í(6.7%)À̾ú´Ù. Ä¡·á¹ÞÀº ȯÀÚ´Â ±â°ü½Äµµ´©°ø(1¸í), Àç¹ß(2¸í), ³úÀüÀÌ(1¸í), ¹Ý´ë Ãø ÆóÀüÀÌ(2¸í)¸¦ µ¿¹ÝÇÑ È¯ÀÚ¿´°í, Ç×¾ÏÁ¦ Ä¡·áÁß ¿øÀÎ ºÒ¸íÀ¸·Î È­Àå½Ç¿¡¼­ »ç¸ÁÇÑ 1¸íÀ» Æ÷ÇÔ 7¸í ¸ðµÎ°¡ »ç¸ÁÇÏ¿´À¸³ª ¹æ»ç¼± Æó·Å¸¸ÀÌ »ç¸Á ¿øÀÎÀ̶ó°í ´ÜÁ¤Çϱâ´Â ¾î·Á¿ü´Ù. ¿µ»óÀÇÇаú¿¡¼­ Áø´ÜµÈ 21¸íÁß CORVUS ½Ã½ºÅÛÀ¸·Î Ä¡·á °èȹÇÑ È¯ÀÚ°¡ 16¸í(23.5%), ECLIPSE·Î °èȹÇÑ È¯ÀÚ´Â 5¸í(13.5%)À̾ CORVUS·Î Ä¡·áÇÑ È¯ÀÚ ±º¿¡¼­ Æó·ÅÀÇ ¹ß»ýÀÌ À¯ÀÇÇÏ°Ô ³ô¾Ò´Ù. ¼ö¼ú Àü ¹æ»ç¼± Ä¡·áȯÀÚ 27¸íÁß 5¸íÀÌ, ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº ȯÀÚ 10¸íÁß 3¸íÀÌ ¹æ»ç¼±Æó·ÅÀ» º¸¿© ¼ö¼úÀÌ ½ÃÇàµÈ ±ºÀÌ ¼ö¼úÀÌ ½ÃÇàµÇÁö ¾ÊÀº ±º¿¡ ºñÇØ »ó´ëÀûÀ¸·Î Àú ¼±·®ÀÓ¿¡µµ ºÒ±¸ÇÏ°í Æó·Å ¹ß»ý·üÀÌ ³ô¾Ò´Ù. V20Àº ¿ìÃø¿¡¼­ 10% ÀÌ»óÀΠȯÀÚ, V10Àº ¿ìÃø¿¡¼­ 20% ÀÌ»óÀΠȯÀÚ¿¡¼­ Åë°èÇÐÀûÀÎ À¯ÀǼºÀ» º¸¿´´Ù.

°á·Ð: ¿µ»óÀÇÇаú¿¡¼­ Æó·ÅÀ¸·Î Áø´ÜµÈ ȯÀÚ´Â 21¸íÀ̾úÀ¸³ª Áõ»óÀÌ ÀÖ¾î Ä¡·á¸¦ ¹ÞÀº ȯÀÚ´Â 7¸í(6.7%)À¸·Î ¼¼±âÁ¶Àý ¹æ»ç¼±Ä¡·á°¡ Á¤»óÁ¶Á÷ÀÇ ¼Õ»óÀ» ÁÙ¿© ÇÕº´ÁõÀ» ÁÙÀÌ´Â µ¥ ±â¿©ÇÏ¿´´Ù°í »ý°¢µÈ´Ù. Åë°èÇÐÀûÀ¸·Î À¯ÀÇÇÑ ¿¹ÈÄÀÎÀڷδ ġ·á ÀüÈÄÀÇ ¼ö¼ú, CORVUS ½Ã½ºÅÛÀ¸·ÎÀÇ Ä¡·á°èȹ, ¿ìÃø, V20ÀÌ 10% ÀÌ»ó, V10ÀÌ 20% ÀÌ»óÀÎ °æ¿ì ¿´°í, ºñ±³Àû ÀûÀº ¹æ»ç¼±·®À» Á¶»ç¹ÞÀº ¼ö¼ú Àü, ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á ȯÀÚ¿¡¼­ ³ôÀº ºñÀ²ÀÇ Áõ»óÀ» µ¿¹ÝÇÑ Æó·ÅÀ» º¸ÀÎ °ÍÀº ÇâÈÄ ¼¼½ÉÇÑ Ä¡·á°èȹÀÌ ÇÊ¿äÇÔÀ» ³ªÅ¸³»¾ú´Ù.

Purpose: To evaluate the incidence and prognostic factors of treatment-related pneumonitis in non-small-cell lung cancer (NSCLC) patients treated with intensity modulated radiation therapy (IMRT).

Materials and Methods: One-hundred-five patients with NSCLC treated with IMRT between 1 August 2004 and 30 November 2006 were analyzed retrospectively. The mean age of patients was 62.9 years, and squamous carcinomas were confirmed in 81 patients (77%). Sixty-six patients (62.9%) were classified as stage III, and 59 patients had lesions in the right lung. Twenty-seven patients were treated with a dose of 3,060 cGy preoperatively, and 10 patients were given a dose of 5,040 cGy postoperatively. Sixty-eight patients received a dose of 7,020 cGy for curative intent. Sixty-eight patients were treated with the use of the CORVUS planning system and 37 patients were treated with the use of the ECLIPSE planning system.

Results: Of 105 patients, 21 patients (20%) had abnormal radiological findings, but only seven patients (6.7%) required treatment for radiation pneumonitis. Six of the seven patients had other serious lesions, including a bronchioesophageal fistula (one patient), recurrence in the treatment field (two patients), brain metastasis (one patient) and lung-to-lung metastasis (two patients); all of these patients died within 19 months after radiation treatment. Sixteen patients (23.5%) that received planning with the CORVUS system had abnormal lung findings. Five patients (13.5%) had abnormal lung findings with the use of the ECLIPSE planning system. Other prognostic factors such as perioperative radiation therapy, a volume over 10% of the V20 volume in the right lung, were also statistically significant.

Conclusion: This retrospective analysis suggests that IMRT could be a beneficial treatment modality for the
reduction of radiation pneumonitis in NSCLC patients. However, the higher incidence of abnormal radiological findings in perioperative patients treated with relatively lower doses (3,060¡­5,040 cGy) suggest the need for judicious treatment planning in preoperative or postoperative treatment.

Å°¿öµå

¼¼±âÁ¶Àý¹æ»ç¼±Ä¡·á;ºñ¼Ò¼¼Æ÷Æó¾Ï;¹æ»ç¼±Æó·Å;¹ß»ý·ü;¿¹ÈÄÀÎÀÚ
Intensitymodulatedradiationtherapy(IMRT);Non-small-celllungcancer(NSCLC);Radiationpneumonitis;Incidencerate;Prognosticfactors

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS